Low LeverageA zero-debt balance sheet materially reduces refinancing and interest-rate risk, giving management financial flexibility to prioritize R&D and clinical timelines. Over a multi-month horizon this lowers solvency risk and makes external financing options less urgent or costly.

Stronger Equity BaseA materially larger equity base improves the company's solvency buffer and extends runway versus prior periods. This reduces immediate dilution pressure, supports ongoing trial investments, and provides a firmer capital foundation for executing its development plan over the next several months.

Focused PipelineHaving a clearly defined lead asset focused on TRPV1 antagonism for diabetes/obesity concentrates resources and strategic clarity. Given the structural, long-term demand for metabolic therapies, a successful clinical readout could create durable commercial optionality and strategic partnership interest.

Bears Say

Persistent Cash BurnConsistent negative operating and free cash flow signals ongoing reliance on external financing to fund operations and clinical development. Over a 2–6 month horizon this elevates execution risk: funding delays or higher-cost raises can slow trials, force scope reductions, or dilute shareholders.

Widening Net LossesGrowing operating losses indicate the company has not yet reached operating leverage and remains in a cash-consuming development phase. Continued widening losses will erode equity buffers over time and increase dependence on capital markets, constraining strategic optionality and R&D pacing.

Very Small, Volatile Revenue BaseA tiny, inconsistent revenue stream provides minimal internal funding and little commercial validation. Combined with limited operational scale, the company faces structural constraints to self-fund development or commercialization, making progress sensitive to financing and partnership outcomes.

5KC FAQ

What was PILA PHARMA AB’s price range in the past 12 months?

PILA PHARMA AB lowest stock price was €0.09 and its highest was €0.41 in the past 12 months.

What is PILA PHARMA AB’s market cap?

PILA PHARMA AB’s market cap is €5.05M.

When is PILA PHARMA AB’s upcoming earnings report date?

PILA PHARMA AB’s upcoming earnings report date is Aug 20, 2026 which is in 164 days.

How were PILA PHARMA AB’s earnings last quarter?

PILA PHARMA AB released its earnings results on Feb 26, 2026. The company reported -€0.034 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.034.

Is PILA PHARMA AB overvalued?

According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PILA PHARMA AB pay dividends?

PILA PHARMA AB does not currently pay dividends.

What is PILA PHARMA AB’s EPS estimate?

PILA PHARMA AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PILA PHARMA AB have?

PILA PHARMA AB has 45,682,120 shares outstanding.

What happened to PILA PHARMA AB’s price movement after its last earnings report?

PILA PHARMA AB reported an EPS of -€0.034 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.869%.

Which hedge fund is a major shareholder of PILA PHARMA AB?

Currently, no hedge funds are holding shares in DE:5KC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PILA PHARMA AB

PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.